• Circio entered a research collaboration with Solid Biosciences to evaluate combined technologies for gene therapies targeting genetic heart disease.
• The collaboration will combine generation 5 circVec constructs with Solid's POLARIS-101 AAV capsid, aiming to reduce therapeutic doses and improve safety.
• Generation 5 circVec has demonstrated up to 200-fold enhanced gene expression from AAV vectors in the heart in vivo.
• Joint laboratory and animal testing could lead to preclinical development of potential therapeutic candidates.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Circio Holding ASA published the original content used to generate this news brief via NewsWeb, the disclosure sustem operated by Euronext Oslo (Ref. ID: 202611110100OSLOBORSNEWS__EN_F1D62FC757A93ECAF34AA97C6323CA3), on November 11, 2026, and is solely responsible for the information contained therein.